| Andrew Tyler Miller, MD | |
|
500 S Maple St, Waconia, MN 55387-1791 | |
| (952) 442-2191 | |
| Not Available |
| Full Name | Andrew Tyler Miller |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 10 Years |
| Location | 500 S Maple St, Waconia, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083022198 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 66523 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ridgeview Medical Center | Waconia, MN | Hospital |
| Ridgeview Sibley Medical Center | Arlington, MN | Hospital |
| Glencoe Regional Health Services | Glencoe, MN | Hospital |
| Minnesota Valley Health Center Inc | Le sueur, MN | Hospital |
| Chi St Alexius Health Williston | Williston, ND | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Allina Health System | 4587573613 | 3071 |
| Consulting Radiologists Ltd | 7719899962 | 78 |
| Ridgeview Medical Center | 9234041997 | 193 |
| Mercy Medical Center | 7416851381 | 30 |
News Archive
A new study has revealed that in addition to testosterone, the masculinization process involves a hormone called androsterone, which originates in other tissues.
GenSpera, Inc. announced that the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom (UK) has cleared for initiation a Phase II human clinical trial of its lead compound, G-202, in the treatment of prostate cancer patients who have failed prior hormonal therapy.
Abbott and BG Medicine, Inc. today announced a development and commercialization agreement for galectin-3, a novel biomarker that may play a role in detecting the development and progression of heart failure. The assay will be developed for Abbott's ARCHITECT immunochemistry instrument platform, specifically the company's i1000SR and i2000SR instruments. The agreement grants Abbott a license to BG Medicine's intellectual property related to galectin-3.
Today's headlines include a number of reports regarding a new proposed rule by the Department of Health and Human Services that will require insurers to justify large premium hikes.
Twelve to 18 months seems to be the ideal length of time between giving birth and getting pregnant again, according to new research from the University of British Columbia and the Harvard T.H. Chan School of Public Health.
› Verified 4 days ago
| Entity Name | Mankato Clinic Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629044029 PECOS PAC ID: 5597677955 Enrollment ID: O20031104000231 |
News Archive
A new study has revealed that in addition to testosterone, the masculinization process involves a hormone called androsterone, which originates in other tissues.
GenSpera, Inc. announced that the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom (UK) has cleared for initiation a Phase II human clinical trial of its lead compound, G-202, in the treatment of prostate cancer patients who have failed prior hormonal therapy.
Abbott and BG Medicine, Inc. today announced a development and commercialization agreement for galectin-3, a novel biomarker that may play a role in detecting the development and progression of heart failure. The assay will be developed for Abbott's ARCHITECT immunochemistry instrument platform, specifically the company's i1000SR and i2000SR instruments. The agreement grants Abbott a license to BG Medicine's intellectual property related to galectin-3.
Today's headlines include a number of reports regarding a new proposed rule by the Department of Health and Human Services that will require insurers to justify large premium hikes.
Twelve to 18 months seems to be the ideal length of time between giving birth and getting pregnant again, according to new research from the University of British Columbia and the Harvard T.H. Chan School of Public Health.
› Verified 4 days ago
| Entity Name | Consulting Radiologists Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487730594 PECOS PAC ID: 7719899962 Enrollment ID: O20031106000511 |
News Archive
A new study has revealed that in addition to testosterone, the masculinization process involves a hormone called androsterone, which originates in other tissues.
GenSpera, Inc. announced that the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom (UK) has cleared for initiation a Phase II human clinical trial of its lead compound, G-202, in the treatment of prostate cancer patients who have failed prior hormonal therapy.
Abbott and BG Medicine, Inc. today announced a development and commercialization agreement for galectin-3, a novel biomarker that may play a role in detecting the development and progression of heart failure. The assay will be developed for Abbott's ARCHITECT immunochemistry instrument platform, specifically the company's i1000SR and i2000SR instruments. The agreement grants Abbott a license to BG Medicine's intellectual property related to galectin-3.
Today's headlines include a number of reports regarding a new proposed rule by the Department of Health and Human Services that will require insurers to justify large premium hikes.
Twelve to 18 months seems to be the ideal length of time between giving birth and getting pregnant again, according to new research from the University of British Columbia and the Harvard T.H. Chan School of Public Health.
› Verified 4 days ago
| Entity Name | Ridgeview Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528364429 PECOS PAC ID: 9234041997 Enrollment ID: O20031111000183 |
News Archive
A new study has revealed that in addition to testosterone, the masculinization process involves a hormone called androsterone, which originates in other tissues.
GenSpera, Inc. announced that the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom (UK) has cleared for initiation a Phase II human clinical trial of its lead compound, G-202, in the treatment of prostate cancer patients who have failed prior hormonal therapy.
Abbott and BG Medicine, Inc. today announced a development and commercialization agreement for galectin-3, a novel biomarker that may play a role in detecting the development and progression of heart failure. The assay will be developed for Abbott's ARCHITECT immunochemistry instrument platform, specifically the company's i1000SR and i2000SR instruments. The agreement grants Abbott a license to BG Medicine's intellectual property related to galectin-3.
Today's headlines include a number of reports regarding a new proposed rule by the Department of Health and Human Services that will require insurers to justify large premium hikes.
Twelve to 18 months seems to be the ideal length of time between giving birth and getting pregnant again, according to new research from the University of British Columbia and the Harvard T.H. Chan School of Public Health.
› Verified 4 days ago
| Entity Name | Glencoe Regional Health Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508885633 PECOS PAC ID: 1759292980 Enrollment ID: O20031119000252 |
News Archive
A new study has revealed that in addition to testosterone, the masculinization process involves a hormone called androsterone, which originates in other tissues.
GenSpera, Inc. announced that the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom (UK) has cleared for initiation a Phase II human clinical trial of its lead compound, G-202, in the treatment of prostate cancer patients who have failed prior hormonal therapy.
Abbott and BG Medicine, Inc. today announced a development and commercialization agreement for galectin-3, a novel biomarker that may play a role in detecting the development and progression of heart failure. The assay will be developed for Abbott's ARCHITECT immunochemistry instrument platform, specifically the company's i1000SR and i2000SR instruments. The agreement grants Abbott a license to BG Medicine's intellectual property related to galectin-3.
Today's headlines include a number of reports regarding a new proposed rule by the Department of Health and Human Services that will require insurers to justify large premium hikes.
Twelve to 18 months seems to be the ideal length of time between giving birth and getting pregnant again, according to new research from the University of British Columbia and the Harvard T.H. Chan School of Public Health.
› Verified 4 days ago
| Entity Name | Madelia Health |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1912999137 PECOS PAC ID: 1254230816 Enrollment ID: O20040102000800 |
News Archive
A new study has revealed that in addition to testosterone, the masculinization process involves a hormone called androsterone, which originates in other tissues.
GenSpera, Inc. announced that the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom (UK) has cleared for initiation a Phase II human clinical trial of its lead compound, G-202, in the treatment of prostate cancer patients who have failed prior hormonal therapy.
Abbott and BG Medicine, Inc. today announced a development and commercialization agreement for galectin-3, a novel biomarker that may play a role in detecting the development and progression of heart failure. The assay will be developed for Abbott's ARCHITECT immunochemistry instrument platform, specifically the company's i1000SR and i2000SR instruments. The agreement grants Abbott a license to BG Medicine's intellectual property related to galectin-3.
Today's headlines include a number of reports regarding a new proposed rule by the Department of Health and Human Services that will require insurers to justify large premium hikes.
Twelve to 18 months seems to be the ideal length of time between giving birth and getting pregnant again, according to new research from the University of British Columbia and the Harvard T.H. Chan School of Public Health.
› Verified 4 days ago
| Entity Name | Stevens Community Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417105552 PECOS PAC ID: 3678475852 Enrollment ID: O20040127000493 |
News Archive
A new study has revealed that in addition to testosterone, the masculinization process involves a hormone called androsterone, which originates in other tissues.
GenSpera, Inc. announced that the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom (UK) has cleared for initiation a Phase II human clinical trial of its lead compound, G-202, in the treatment of prostate cancer patients who have failed prior hormonal therapy.
Abbott and BG Medicine, Inc. today announced a development and commercialization agreement for galectin-3, a novel biomarker that may play a role in detecting the development and progression of heart failure. The assay will be developed for Abbott's ARCHITECT immunochemistry instrument platform, specifically the company's i1000SR and i2000SR instruments. The agreement grants Abbott a license to BG Medicine's intellectual property related to galectin-3.
Today's headlines include a number of reports regarding a new proposed rule by the Department of Health and Human Services that will require insurers to justify large premium hikes.
Twelve to 18 months seems to be the ideal length of time between giving birth and getting pregnant again, according to new research from the University of British Columbia and the Harvard T.H. Chan School of Public Health.
› Verified 4 days ago
| Entity Name | Noran Neurological Clinic, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710098306 PECOS PAC ID: 3971497389 Enrollment ID: O20040209000324 |
News Archive
A new study has revealed that in addition to testosterone, the masculinization process involves a hormone called androsterone, which originates in other tissues.
GenSpera, Inc. announced that the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom (UK) has cleared for initiation a Phase II human clinical trial of its lead compound, G-202, in the treatment of prostate cancer patients who have failed prior hormonal therapy.
Abbott and BG Medicine, Inc. today announced a development and commercialization agreement for galectin-3, a novel biomarker that may play a role in detecting the development and progression of heart failure. The assay will be developed for Abbott's ARCHITECT immunochemistry instrument platform, specifically the company's i1000SR and i2000SR instruments. The agreement grants Abbott a license to BG Medicine's intellectual property related to galectin-3.
Today's headlines include a number of reports regarding a new proposed rule by the Department of Health and Human Services that will require insurers to justify large premium hikes.
Twelve to 18 months seems to be the ideal length of time between giving birth and getting pregnant again, according to new research from the University of British Columbia and the Harvard T.H. Chan School of Public Health.
› Verified 4 days ago
| Entity Name | St Francis Regional Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447605514 PECOS PAC ID: 7214821909 Enrollment ID: O20040212000408 |
News Archive
A new study has revealed that in addition to testosterone, the masculinization process involves a hormone called androsterone, which originates in other tissues.
GenSpera, Inc. announced that the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom (UK) has cleared for initiation a Phase II human clinical trial of its lead compound, G-202, in the treatment of prostate cancer patients who have failed prior hormonal therapy.
Abbott and BG Medicine, Inc. today announced a development and commercialization agreement for galectin-3, a novel biomarker that may play a role in detecting the development and progression of heart failure. The assay will be developed for Abbott's ARCHITECT immunochemistry instrument platform, specifically the company's i1000SR and i2000SR instruments. The agreement grants Abbott a license to BG Medicine's intellectual property related to galectin-3.
Today's headlines include a number of reports regarding a new proposed rule by the Department of Health and Human Services that will require insurers to justify large premium hikes.
Twelve to 18 months seems to be the ideal length of time between giving birth and getting pregnant again, according to new research from the University of British Columbia and the Harvard T.H. Chan School of Public Health.
› Verified 4 days ago
| Entity Name | Minnesota Valley Health Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730248907 PECOS PAC ID: 9032006507 Enrollment ID: O20040301000309 |
News Archive
A new study has revealed that in addition to testosterone, the masculinization process involves a hormone called androsterone, which originates in other tissues.
GenSpera, Inc. announced that the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom (UK) has cleared for initiation a Phase II human clinical trial of its lead compound, G-202, in the treatment of prostate cancer patients who have failed prior hormonal therapy.
Abbott and BG Medicine, Inc. today announced a development and commercialization agreement for galectin-3, a novel biomarker that may play a role in detecting the development and progression of heart failure. The assay will be developed for Abbott's ARCHITECT immunochemistry instrument platform, specifically the company's i1000SR and i2000SR instruments. The agreement grants Abbott a license to BG Medicine's intellectual property related to galectin-3.
Today's headlines include a number of reports regarding a new proposed rule by the Department of Health and Human Services that will require insurers to justify large premium hikes.
Twelve to 18 months seems to be the ideal length of time between giving birth and getting pregnant again, according to new research from the University of British Columbia and the Harvard T.H. Chan School of Public Health.
› Verified 4 days ago
| Entity Name | Allina Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295272342 PECOS PAC ID: 4587573613 Enrollment ID: O20040319000460 |
News Archive
A new study has revealed that in addition to testosterone, the masculinization process involves a hormone called androsterone, which originates in other tissues.
GenSpera, Inc. announced that the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom (UK) has cleared for initiation a Phase II human clinical trial of its lead compound, G-202, in the treatment of prostate cancer patients who have failed prior hormonal therapy.
Abbott and BG Medicine, Inc. today announced a development and commercialization agreement for galectin-3, a novel biomarker that may play a role in detecting the development and progression of heart failure. The assay will be developed for Abbott's ARCHITECT immunochemistry instrument platform, specifically the company's i1000SR and i2000SR instruments. The agreement grants Abbott a license to BG Medicine's intellectual property related to galectin-3.
Today's headlines include a number of reports regarding a new proposed rule by the Department of Health and Human Services that will require insurers to justify large premium hikes.
Twelve to 18 months seems to be the ideal length of time between giving birth and getting pregnant again, according to new research from the University of British Columbia and the Harvard T.H. Chan School of Public Health.
› Verified 4 days ago
| Entity Name | Warren Community Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073516357 PECOS PAC ID: 2264408566 Enrollment ID: O20040908000953 |
News Archive
A new study has revealed that in addition to testosterone, the masculinization process involves a hormone called androsterone, which originates in other tissues.
GenSpera, Inc. announced that the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom (UK) has cleared for initiation a Phase II human clinical trial of its lead compound, G-202, in the treatment of prostate cancer patients who have failed prior hormonal therapy.
Abbott and BG Medicine, Inc. today announced a development and commercialization agreement for galectin-3, a novel biomarker that may play a role in detecting the development and progression of heart failure. The assay will be developed for Abbott's ARCHITECT immunochemistry instrument platform, specifically the company's i1000SR and i2000SR instruments. The agreement grants Abbott a license to BG Medicine's intellectual property related to galectin-3.
Today's headlines include a number of reports regarding a new proposed rule by the Department of Health and Human Services that will require insurers to justify large premium hikes.
Twelve to 18 months seems to be the ideal length of time between giving birth and getting pregnant again, according to new research from the University of British Columbia and the Harvard T.H. Chan School of Public Health.
› Verified 4 days ago
| Entity Name | Glencoe Regional Health Services |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1508885633 PECOS PAC ID: 1759292980 Enrollment ID: O20060504000699 |
News Archive
A new study has revealed that in addition to testosterone, the masculinization process involves a hormone called androsterone, which originates in other tissues.
GenSpera, Inc. announced that the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom (UK) has cleared for initiation a Phase II human clinical trial of its lead compound, G-202, in the treatment of prostate cancer patients who have failed prior hormonal therapy.
Abbott and BG Medicine, Inc. today announced a development and commercialization agreement for galectin-3, a novel biomarker that may play a role in detecting the development and progression of heart failure. The assay will be developed for Abbott's ARCHITECT immunochemistry instrument platform, specifically the company's i1000SR and i2000SR instruments. The agreement grants Abbott a license to BG Medicine's intellectual property related to galectin-3.
Today's headlines include a number of reports regarding a new proposed rule by the Department of Health and Human Services that will require insurers to justify large premium hikes.
Twelve to 18 months seems to be the ideal length of time between giving birth and getting pregnant again, according to new research from the University of British Columbia and the Harvard T.H. Chan School of Public Health.
› Verified 4 days ago
| Entity Name | Christian Unity Hospital Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558423665 PECOS PAC ID: 8123925401 Enrollment ID: O20111012000177 |
News Archive
A new study has revealed that in addition to testosterone, the masculinization process involves a hormone called androsterone, which originates in other tissues.
GenSpera, Inc. announced that the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom (UK) has cleared for initiation a Phase II human clinical trial of its lead compound, G-202, in the treatment of prostate cancer patients who have failed prior hormonal therapy.
Abbott and BG Medicine, Inc. today announced a development and commercialization agreement for galectin-3, a novel biomarker that may play a role in detecting the development and progression of heart failure. The assay will be developed for Abbott's ARCHITECT immunochemistry instrument platform, specifically the company's i1000SR and i2000SR instruments. The agreement grants Abbott a license to BG Medicine's intellectual property related to galectin-3.
Today's headlines include a number of reports regarding a new proposed rule by the Department of Health and Human Services that will require insurers to justify large premium hikes.
Twelve to 18 months seems to be the ideal length of time between giving birth and getting pregnant again, according to new research from the University of British Columbia and the Harvard T.H. Chan School of Public Health.
› Verified 4 days ago
| Entity Name | Sibley Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740240225 PECOS PAC ID: 3870722499 Enrollment ID: O20140418000315 |
News Archive
A new study has revealed that in addition to testosterone, the masculinization process involves a hormone called androsterone, which originates in other tissues.
GenSpera, Inc. announced that the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom (UK) has cleared for initiation a Phase II human clinical trial of its lead compound, G-202, in the treatment of prostate cancer patients who have failed prior hormonal therapy.
Abbott and BG Medicine, Inc. today announced a development and commercialization agreement for galectin-3, a novel biomarker that may play a role in detecting the development and progression of heart failure. The assay will be developed for Abbott's ARCHITECT immunochemistry instrument platform, specifically the company's i1000SR and i2000SR instruments. The agreement grants Abbott a license to BG Medicine's intellectual property related to galectin-3.
Today's headlines include a number of reports regarding a new proposed rule by the Department of Health and Human Services that will require insurers to justify large premium hikes.
Twelve to 18 months seems to be the ideal length of time between giving birth and getting pregnant again, according to new research from the University of British Columbia and the Harvard T.H. Chan School of Public Health.
› Verified 4 days ago
| Entity Name | Allina Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457657249 PECOS PAC ID: 4587573613 Enrollment ID: O20221213001713 |
News Archive
A new study has revealed that in addition to testosterone, the masculinization process involves a hormone called androsterone, which originates in other tissues.
GenSpera, Inc. announced that the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom (UK) has cleared for initiation a Phase II human clinical trial of its lead compound, G-202, in the treatment of prostate cancer patients who have failed prior hormonal therapy.
Abbott and BG Medicine, Inc. today announced a development and commercialization agreement for galectin-3, a novel biomarker that may play a role in detecting the development and progression of heart failure. The assay will be developed for Abbott's ARCHITECT immunochemistry instrument platform, specifically the company's i1000SR and i2000SR instruments. The agreement grants Abbott a license to BG Medicine's intellectual property related to galectin-3.
Today's headlines include a number of reports regarding a new proposed rule by the Department of Health and Human Services that will require insurers to justify large premium hikes.
Twelve to 18 months seems to be the ideal length of time between giving birth and getting pregnant again, according to new research from the University of British Columbia and the Harvard T.H. Chan School of Public Health.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Andrew Tyler Miller, MD 500 S Maple St, Waconia, MN 55387-1791 Ph: (952) 442-2191 | Andrew Tyler Miller, MD 500 S Maple St, Waconia, MN 55387-1791 Ph: (952) 442-2191 |
News Archive
A new study has revealed that in addition to testosterone, the masculinization process involves a hormone called androsterone, which originates in other tissues.
GenSpera, Inc. announced that the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom (UK) has cleared for initiation a Phase II human clinical trial of its lead compound, G-202, in the treatment of prostate cancer patients who have failed prior hormonal therapy.
Abbott and BG Medicine, Inc. today announced a development and commercialization agreement for galectin-3, a novel biomarker that may play a role in detecting the development and progression of heart failure. The assay will be developed for Abbott's ARCHITECT immunochemistry instrument platform, specifically the company's i1000SR and i2000SR instruments. The agreement grants Abbott a license to BG Medicine's intellectual property related to galectin-3.
Today's headlines include a number of reports regarding a new proposed rule by the Department of Health and Human Services that will require insurers to justify large premium hikes.
Twelve to 18 months seems to be the ideal length of time between giving birth and getting pregnant again, according to new research from the University of British Columbia and the Harvard T.H. Chan School of Public Health.
› Verified 4 days ago
Robert Aaron Yost, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 500 S Maple St, Waconia, MN 55387 Phone: 952-777-5553 | |
Stephanie Krejcarek Childs, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 560 S Maple St Ste 10, Waconia, MN 55387 Phone: 952-442-6000 | |
Mark William Doyscher, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 500 S Maple St, Waconia, MN 55387 Phone: 952-777-5553 Fax: 952-442-8055 | |
Paul W Sperduto, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 490 S Maple St, # 117, Waconia, MN 55387 Phone: 952-442-6000 Fax: 952-442-6004 |